The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro
Abstract
Amyloid diseases are caused by the self-assembly of a given protein into an insoluble cross-beta-sheet quaternary structural form which is pathogenic. An understanding of the biochemical mechanism of amyloid fibril formation should prove useful in understanding amyloid disease. Toward this end, a procedure for the conversion of the amyloidogenic protein transthyretin into amyloid fibrils under conditions which mimic the acidic environment of a lysosome has been developed. Association of a structured transthyretin denaturation intermediate is sufficient for amyloid fibril formation in vitro. The rate of fibril formation is pH dependent with significant rates being observed at pHs accessible within the lysosome (3.6-4.8). Far-UV CD spectroscopic studies suggest that transthyretin retains its secondary structural features at pHs where fibrils are formed. Near-UV CD studies demonstrate that transthyretin has retained the majority of its tertiary structure during fibril formation as well. Near-UV CD analysis in combination with glutaraldehyde cross-linking studies suggests that a pH-mediated tetramer to monomer transition is operative in the pH range where fibril formation occurs. The rate of fibril formation decreases markedly at pHs below pH 3.6, consistent with denaturation to a monomeric TTR intermediate which has lost its native tertiary structure and capability to form fibrils. It is difficult to specify with certainty which quaternary structural form of transthyretin is the amyloidogenic intermediate at this time. These difficulties arise because the maximal rate of fibril formation occurs at pH 3.6 where tetramer, traces of dimer, and significant amounts of monomer are observed.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
ON THE BINDING OF CONGO RED BY AMYLOID
PUCHTLER, H., SWEAT, F., & LEVINE, M. (1962) · Journal of Histochemistry & Cytochemistry · doi:10.1177/10.3.355 · Cited by 1,128
Evidence that β-Amyloid Protein in Alzheimer's Disease Is Not Derived by Normal Processing
Sisodia, S. S., Koo, E. H., Beyreuther, K., Unterbeck, A., & Price, D. L. (1990) · Science · doi:10.1126/science.1691865 · Cited by 893
Blake, C. C. F., Geisow, M. J., Oatley, S. J., Rérat, B., & Rérat, C. (1978) · Journal of Molecular Biology · doi:10.1016/0022-2836(78)90368-6 · Cited by 791
Processing of the Amyloid Protein Precursor to Potentially Amyloidogenic Derivatives
Golde, T. E., Estus, S., Younkin, L. H., Selkoe, D. J., & Younkin, S. G. (1992) · Science · doi:10.1126/science.1738847 · Cited by 737
Fibril in senile systemic amyloidosis is derived from normal transthyretin.
Westermark, P., Sletten, K., Johansson, B., & Cornwell, G. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2843 · Cited by 696
Folding and association of proteins
Jaenicke, R. (1987) · Progress in Biophysics and Molecular Biology · doi:10.1016/0079-6107(87)90011-3 · Cited by 691
Klunk, W. E., Pettegrew, J. W., & Abraham, D. J. (1989) · Journal of Histochemistry & Cytochemistry · doi:10.1177/37.8.2666510 · Cited by 623
Mechanism of acid-induced folding of proteins
Goto, Y., Takahashi, N., & Fink, A. L. (1990) · Biochemistry · doi:10.1021/bi00466a009 · Cited by 566
An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P.
Kowall, N. W., Beal, M. F., Busciglio, J., Duffy, L. K., & Yankner, B. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.16.7247 · Cited by 522
Cited by
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Common core structure of amyloid fibrils by synchrotron X-ray diffraction 1 1Edited by F. E. Cohen
Sunde, M., Serpell, L. C., Bartlam, M., Fraser, P. E., Pepys, M. B., & Blake, C. C. F. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1348 · Cited by 1,707
Stefani, M., & Dobson, C. M. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0464-5 · Cited by 1,651
Protein aggregation: folding aggregates, inclusion bodies and amyloid
Fink, A. L. (1998) · Folding and Design · doi:10.1016/s1359-0278(98)00002-9 · Cited by 1,157
The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways
Kelly, J. W. (1998) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(98)80016-x · Cited by 1,001
Self-citationThe protofilament structure of insulin amyloid fibrils
Jiménez, J. L., Nettleton, E. J., Bouchard, M., Robinson, C. V., Dobson, C. M., & Saibil, H. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142459399 · Cited by 834
Amyloid formation by globular proteins under native conditions
Chiti, F., & Dobson, C. M. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.131 · Cited by 812
Therapeutic approaches to protein-misfolding diseases
Cohen, F. E., & Kelly, J. W. (2003) · Nature · doi:10.1038/nature02265 · Cited by 800
Self-citation3D domain swapping: A mechanism for oligomer assembly
Bennett, M. J., Schlunegger, M. P., & Eisenberg, D. (1995) · Protein Science · doi:10.1002/pro.5560041202 · Cited by 764
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
Bulawa, C. E., Connelly, S., DeVit, M., Wang, L., Weigel, C., Fleming, J. A., Packman, J., Powers, E. T., Wiseman, R. L., Foss, T. R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121005109 · Cited by 742
Self-citationRepurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial
Berk, J. L., Suhr, O. B., Obici, L., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., et al. (2013) · JAMA · doi:10.1001/jama.2013.283815 · Cited by 708
Self-citationAlternative conformations of amyloidogenic proteins govern their behavior
Kelly, J. W. (1996) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(96)80089-3 · Cited by 593
Self-citationHalf a century of amyloids: past, present and future
Ke, P. C., Zhou, R., Serpell, L. C., Riek, R., Knowles, T. P. J., Lashuel, H. A., Gazit, E., Hamley, I. W., Davis, T. P., Fändrich, M., et al. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00199a · Cited by 568
Defective protein folding as a basis of human disease
Thomas, P. J., Qu, B.-H., & Pedersen, P. L. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89100-8 · Cited by 529
Structural Studies of Amyloid Proteins at the Molecular Level
Eisenberg, D. S., & Sawaya, M. R. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045104 · Cited by 523
Amyloid fibrils: Abnormal protein assembly
Rambaran, R. N., & Serpell, L. C. (2008) · Prion · doi:10.4161/pri.2.3.7488 · Cited by 511
The activities of amyloids from a structural perspective
Riek, R., & Eisenberg, D. S. (2016) · Nature · doi:10.1038/nature20416 · Cited by 508
The Biological and Chemical Basis for Tissue-Selective Amyloid Disease
Sekijima, Y., Wiseman, R. L., Matteson, J., Hammarström, P., Miller, S. R., Sawkar, A. R., Balch, W. E., & Kelly, J. W. (2005) · Cell · doi:10.1016/j.cell.2005.01.018 · Cited by 488
Self-citationFormation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy
Bouchard, M., Zurdo, J., Nettleton, E. J., Dobson, C. M., & Robinson, C. V. (2000) · Protein Science · doi:10.1110/ps.9.10.1960 · Cited by 482
The expanding amyloid family: Structure, stability, function, and pathogenesis
Sawaya, M. R., Hughes, M. P., Rodriguez, J. A., Riek, R., & Eisenberg, D. S. (2021) · Cell · doi:10.1016/j.cell.2021.08.013 · Cited by 475
Protein misfolding and aggregation in cataract disease and prospects for prevention
Moreau, K. L., & King, J. A. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.03.005 · Cited by 450
Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease
Adams, D., Koike, H., Slama, M., & Coelho, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0210-4 · Cited by 448
Folding versus aggregation: Polypeptide conformations on competing pathways
Jahn, T. R., & Radford, S. E. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.05.015 · Cited by 428
Targeting protein aggregation for the treatment of degenerative diseases
Eisele, Y. S., Monteiro, C., Fearns, C., Encalada, S. E., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4593 · Cited by 419
Self-citationA kinetic model for amyloid formation in the prion diseases: importance of seeding.
Come, J. H., Fraser, P. E., & Lansbury, P. T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.5959 · Cited by 394
Classification of Acid Denaturation of Proteins: Intermediates and Unfolded States
Fink, A. L., Calciano, L. J., Goto, Y., Kurotsu, T., & Palleros, D. R. (1994) · Biochemistry · doi:10.1021/bi00207a018 · Cited by 389
Amyloid β-Protein Oligomerization
Bitan, G., Lomakin, A., & Teplow, D. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102223200 · Cited by 387
Blake, C., & Serpell, L. (1996) · Structure · doi:10.1016/s0969-2126(96)00104-9 · Cited by 376
Sanchez-Ruiz, J. M. (2010) · Biophysical Chemistry · doi:10.1016/j.bpc.2010.02.004 · Cited by 367
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity
Hammarström, P., Jiang, X., Hurshman, A. R., Powers, E. T., & Kelly, J. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202495199 · Cited by 359
Self-citationA role for destabilizing amino acid replacements in light-chain amyloidosis.
Hurle, M. R., Helms, L. R., Li, L., Chan, W., & Wetzel, R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5446 · Cited by 348
Inhibiting transthyretin amyloid fibril formation via protein stabilization
Miroy, G. J., Lai, Z., Lashuel, H. A., Peterson, S. A., Strang, C., & Kelly, J. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15051 · Cited by 344
Self-citationConformational Abs recognizing a generic amyloid fibril epitope
O'Nuallain, B., & Wetzel, R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022662599 · Cited by 333
Sekijima, Y. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308724 · Cited by 332
Johnson, S. M., Connelly, S., Fearns, C., Powers, E. T., & Kelly, J. W. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.060 · Cited by 328
Self-citationPrion-inducing domain 2–114 of yeast Sup35 protein transforms in vitro into amyloid-like filaments
King, C.-Y., Tittmann, P., Gross, H., Gebert, R., Aebi, M., & Wüthrich, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6618 · Cited by 311
Amyloid formation under physiological conditions proceeds via a native-like folding intermediate
Jahn, T. R., Parker, M. J., Homans, S. W., & Radford, S. E. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1058 · Cited by 305
Johnson, S. M., Wiseman, R. L., Sekijima, Y., Green, N. S., Adamski-Werner, S. L., & Kelly, J. W. (2005) · Accounts of Chemical Research · doi:10.1021/ar020073i · Cited by 303
Self-citationDistinct β-sheet structure in protein aggregates determined by ATR-FTIR spectroscopy
Shivu, B., Seshadri, S., Li, J., Oberg, K. A., Uversky, V. N., & Fink, A. L. (2013) · Biochemistry · doi:10.1021/bi400625v · Cited by 289
Lashuel, H. A., LaBrenz, S. R., Woo, L., Serpell, L. C., & Kelly, J. W. (2000) · Journal of the American Chemical Society · doi:10.1021/ja9937831 · Cited by 285
Self-citationMizejewski, G. J. (2001) · Experimental Biology and Medicine · doi:10.1177/153537020122600503 · Cited by 269
Inhibition of Amyloid Formation
Härd, T., & Lendel, C. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.062 · Cited by 269
Sekijima, Y., Dendle, M. A., & Kelly, J. W. (2006) · Amyloid · doi:10.1080/13506120600960882 · Cited by 268
Self-citationTransthyretin: a review from a structural perspective
Hamilton, J. A., & Benson, M. D. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000791 · Cited by 264
Therapeutic strategies for human amyloid diseases
Sacchettini, J. C., & Kelly, J. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd769 · Cited by 261
Self-citationThioflavine T interaction with amyloid β-sheet structures
LeVine, H. (1995) · Amyloid · doi:10.3109/13506129509031881 · Cited by 253
Molecular conformation of a peptide fragment of transthyretin in an amyloid fibril
Jaroniec, C. P., MacPhee, C. E., Astrof, N. S., Dobson, C. M., & Griffin, R. G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252625999 · Cited by 253
Neurotoxic protein oligomers — what you see is not always what you get
Bitan, G., Fradinger, E. A., Spring, S. M., & Teplow, D. B. (2005) · Amyloid · doi:10.1080/13506120500106958 · Cited by 221
A molecular mechanism for transthyretin amyloidogenesis
Yee, A. W., Aldeghi, M., Blakeley, M. P., Ostermann, A., Mas, P. J., Moulin, M., de Sanctis, D., Bowler, M. W., Mueller-Dieckmann, C., Mitchell, E. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08609-z · Cited by 139
Cell and molecular biology of transthyretin and thyroid hormones
Richardson, S. J. (2007) · International Review of Cytology · doi:10.1016/s0074-7696(07)58003-4 · Cited by 116
Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis
Butler, J. S., Chan, A., Costelha, S., Fishman, S., Willoughby, J. L. S., Borland, T. D., Milstein, S., Foster, D. J., Gonçalves, P., Chen, Q., et al. (2016) · Amyloid · doi:10.3109/13506129.2016.1160882 · Cited by 113
Convertino, M., Das, J., & Dokholyan, N. V. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00195 · Cited by 105
Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma
Choi, S., Connelly, S., Reixach, N., Wilson, I. A., & Kelly, J. W. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.281 · Cited by 90
Self-citationGonçalves, N. P., Teixeira-Coelho, M., & Saraiva, M. J. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.030 · Cited by 27
Metadata
- Authors
- Colon, W., & Kelly, J. W.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1992-09-15
- Volume
- 31
- Issue
- 36
- Pages
- 8654-8660
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2011606718
- Cited by
- 573
- References
- 34
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.